- Cytolon and T-Cell Europe agree on cooperation
- Cytolon initiates global development of DIT - Distributed-Inventory-TechnologyTM
- Cytolon joins Personalized Medicine Coalition
- Cytolon successful with second financing round
- Cytolon gains Patent for CordMatch® in Australia
- Cytolon and DKMS Cord Blood Bank announce collaboration for CordMatch’s Beta-Testing Phase
- Timm Jessen Joins Cytolon’s Supervisory Board
- Cytolon Partners with iSoft for New Life Science Research Tool
- Michaela Servas joins Cytolon´s Supervisory Board
- Cytolon Co-Founder Prof. Dr. Joachim Dudenhausen receives Order of Merit
- CordMatch® goes live
- Cytolon Partners with CSC to Develop CordMatch®
- Cytolon Closes Its First Round of Financing
- Wolfgang Jünger Joins Cytolon's Supervisory Board
- Katherina Reiche, MdB, Steps Down From Cytolon's Supervisory Board to Become a Member of the Federal Government of Germany
- Cytolon Receives the "MOST PROMISING COMPANY LAUNCHED IN 2009 AWARD"
- Cytolon Announces Cooperative Agreement with ARCWAY
- Start-up Financing Begins
- The Launching of Cytolon AG
Cytolon and T-Cell Europe agree on cooperation
Cytolon AG and T-Cell Europe GmbH (TCell) announced their cooperation today. TCell will start using Cytolon´s IT-matching-system CordMatch® for all its allogenic T-cell products.
Berlin, February 21, 2012. Cytolon AG and T-Cell Europe GmbH (TCell) announced their cooperation today. TCell, which develops T-cell based therapies, will start using Cytolon´s IT-matching-system CordMatch® for all its allogenic T-cell products.
Thomas Klein, Cytolon’s Founder and Chief Executive Officer, said “The market of T-cell transplants is becoming more competitive. In order for TCell to remain successful in this field and to establish a state-of-the-art T-cell bank we are happy to support TCell´s searching and matching process. Cytolon on its part will make adequate investments and efforts to ensure a high quality IT-matching-system which will also integrate TCell´s needs and requirements.“
Dr. Claudia Ulbrich, Chief Executive Officer of T-Cell Europe, said “We are looking very much forward to working with Cytolon´s matching platform CordMatch®. As the use of T-cells play an increasingly important role in regenerative medicine and transplantation medicine we believe that it is essential to offer improved solutions for ensuring an efficient and effective searching, matching and processing of T-cells. CordMatch® is the perfect tool for us.”
About Cytolon
Cytolon AG is a technology oriented service provider positioning itself as the first company worldwide to offer intelligent internet platforms that will become necessary for the field of personalized medicine. Cytolon’s first product is an internet based matching platform, CordMatch®. CordMatch® offers efficient cost saving solutions to transplant centers, donor registries, cord blood banks, and pharmaceutical companies which make it possible to provide individually matched stem cell preparations for a high number of cases worldwide. Thomas Klein founded Cytolon AG in 2008. In 2009 Cytolon was awarded the “most promising company launched-Award by Deutsche Bank, Hasso Plattner Ventures. Cytolon is a member of the Association of Research-Based Pharmaceutical Companies (VfA) and the Federal Association for Information Technology, Telecommunications and New Media (BITKOM). Further information can be found at www.cytolon.com.
About TCell
T-Cell Europe GmbH (TCell) is a spin-off-company of the Berlin-Brandenburg-Center for Regenerative Therapies (BCRT), an internationally leading translational center for cell-based-therapies (www.b-crt.de). Employing its proprietary platform technologies, TCell´s objective is to develop and commercialize new T-Cell-based therapies. Its first indication product will be a T-Cell product for kidney transplantation.